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Ho and colleagues recently drew attention to the conse-
quences of co-infection with Influenza and HIV.1 We present
four cases of combined infection with influenza and Middle
East Respiratory Syndrome Coronavirus (MERS-CoV) infec-
tion. Nasopharyngeal swabs or tracheal aspirates were
tested for MERS-CoV using real-time reverse-transcription
polymerase chain reaction (RT-PCR).2,3 Samples were tested
for Influenza A, B and H1N1 by rapid molecular test (Gen-
EXper for detection of flu A, B and 2009 H1N1, Cepheid).
Case 1
In the first case, a 39 year-old male, health care worker, an
engineer who became ill seven days before admission. He had
fever >38 C, cough and sore throat. He had no nausea,
vomiting, diarrhoea or shortness of breath (SOB). He denied
history of travel or contact with positive case or camels. He
was febrile with a temperature of 39.5 C. Chest X-ray
showed non-homogenous opacity at the lower right lung
zone. A nasopharyngeal swab was positive for MERS-CoV with
Ct value upE gene 34, and ORF1A 34 (Table 1). The test was
negative for influenza but a repeat swab after 48 h was nega-
tive for MERS-CoV and positive for H1N1. The patient
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received azithromycin, ceftriaxone and oseltamivir. The pa-
tient was discharged home after two negative swabs of
MERS-CoV and being asymptomatic for 48 h.
Case 2
In the second case, a 61 year-old female with diabetes
mellitus and dyslipidemia was admitted with a three-day
history of shortness of breath and productive cough. She
had no nausea, vomiting, or diarrhoea. She denied history
of travel or contact with positive case or camels. She was
afebrile with a temperature of 37 C. Chest X-ray showed
patchy opacities involving middle and lower zones of both
lung fields.
A nasopharyngeal swab was positive for MERS-CoV
with Ct value upE gene 34, ORF1A 35 and negative for influ-
enza. A repeat swab after 48 h was negative for MERS-CoV
but positive for H1N1. She required BIPAP and she was sub-
sequently intubated and was started on mechanical ventila-
tion. She was extubated after 13 days. The patient received
piperacillinetazobactam, and erythromycin. The patient
was discharged home after she had 2 negative swabs of
MERS-CoV and being asymptomatic for 48 h.
Case 3
In the third case, a 29 year-old housekeeper female was
admitted with two days history of fever and cough. She had
no nausea, vomiting, diarrhoea nor shortness of breathing.
She had a history of contactwithMERS-CoV positive case. She
was afebrile with a temperature of 36.9 C. Chest X-ray was
normal. A nasopharyngeal swab collected upon presentation
was positive for MERS-CoV with CT value upE gene 32 ORF1A
32. The swabwas negative for influenza. A repeated swab af-
ter 48 hwas positiveMERS-CoVand positive for H1N1. The pa-
tient received oseltamivir, azithromycin and ceftriaxone.
The patient was discharged home after she had 2 negative
swab of MERS-CoV and being asymptomatic for 48 h.
Case 4
In the fourth case, thepatientwas a 73 year-old femalewith a
history of hypothyroidism, heart failure, lymphoma, and lung
fibrosis. She has no history of travel or contact with positive
case or camels. Four days prior to her presentation, she had
productive cough and shortness of breath. She had no fever,
diarrhoea, vomiting or nausea. She was afebrile with a
temperature of 36.7 C. Chest X-ray showed bilateral diffuse
infiltrate (Fig. 1). A nasopharyngeal swab was positive for
MERS-CoV with Ct value upE gene 37; ORF1A 36 and negative
for Influenza. A repeat swab after 3 days was negative for
MERS-CoV but positive for influenza A. The patient was
treatedwith piperacillinetazobactam for six days and oselta-
mivir for 5 days. The patient was discharged home after two
negative MERS-CoV and being asymptomatic for 48 h.
These patients highlight the co-infection with MERS-CoV
and influenza. The exact reason to have a negative influenza
test at the time of positive MERS-CoV is not completely
understood. It is possible that the presence of MERS-CoV
inhibits the PCR reaction for influenza virus. However, an
earlier case of MERS-CoV tested initially positive for influenza
A(H1N1)pdm09.4 On the other hand, the positivity of nasal
swabs for influenza is specimen type and technique depen-
dent.5 Thus, initially negative influenza tests could be a false
test result. Positive results for viral respiratory pathogens
should not preclude testing for MERS-CoV because co-
infection can occur.6 Only a small number of MERS cases had
co-infection with influenza A, parainfluenza, herpes simplex,
and Streptococcus pneumoniae.7 In one case, a co-infection
with Herpes simplex virus type 1 DNA13 and rhinovirus
RNA14 were detected by RT-PCR.8 The investigation of the
first 47 cases showed no co-infection with MERS-CoV.2 There
is a controversy regarding the risk of increased or decreased
severity of co-infections. For example co-infections with Res-
piratory Syncytial Virus (RSV) and human meta-pneumovirus
(hMPV) causes more severe infection than either virus alone
with longer hospitalization and oxygen requirement.9 Other
studies did not demonstrate these effects.10 The association
and the impact of co-infection with MERS-CoV and influenza
viruses deserve further evaluation and studies.
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Completeness of case ascertainment and
availability of environmental data in
Legionnaires’ disease enhanced
surveillance in England, 2012e2014
To the Editor,
Bai et al.1 previously highlighted the importance of
effective communicable disease surveillance in China for
the detection of outbreaks to inform infectious disease
prevention and control. To achieve similar aims with rela-
tion to the control of Legionnaires’ disease in England a na-
tional enhanced surveillance scheme operates.
Surveillance data must be both complete and as timely as
possible, as highlighted by Freeman et al. in this journal.2
Thereforewesought toassess the completeness of caseascer-
tainment in addition to the availability of environmental data
reported to the national enhanced legionella surveillance
scheme (NELSS) for residents in England. The valueof environ-
mental data is particularly important for Legionnaires’ dis-
ease in order to inform the attribution of potential
environmental sources of cases and clusters of this infection.
In England, the National Legionella Surveillance Team
(NLST) leads on surveillance and control of Legionnaires’
disease, while Field Epidemiology Services (FES) teams
collect surveillance data and investigate sporadic cases,
clusters and outbreaks in conjunction with local Health
Protection Teams (HPTs). The NLST worked with the FES
teams in the North West (NW) and West Midlands (WMids)
regions of England to audit the reporting of Legionella cases
with onset dates during each calendar year between 2012
and 2014, inclusive. Eligible cases were those cases of
Legionella spp. infections resident in either of these re-
gions in England, which were laboratory confirmed by uri-
nary antigen testing, culture or serological testing. These
cases were identified in the month of February following
each calendar year by the NLST and were compared to
those known by the FES teams for NW and WMids regions.
Completeness of case ascertainment was calculated as
the proportion of cases recorded by FES teams for cases
with onset of symptoms between 2012 and 2014 inclusive
which were reported to the NLST. The availability of
environmental data reported to the national enhanced
surveillance scheme was calculated as the proportion of
cases during the same time period with any environmental
investigation data reported to the NLST.
The results are summarised in Table 1; in the NW region, a
mean of 34 cases were reported per year between 2012 and
2014. In the WMids region, the mean number of cases per
year was 46. Both regions reported 100% of cases to the NLST.
Mean availability of environmental data reported was
80.8% in the NW and 42.8% in WMids. However, there was a
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